UVA Health researchers have discovered a potential way to predict which patients with severe COVID-19 are likely to recover well and which are likely to suffer “long-haul” lung problems.
ADCs dominate with billion-dollar licensing agreements in 2022
ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs to target and eliminate cancer cells. Credit: ArtemisDiana via shutterstock. Antibody-drug conjugates